Indiana Alzheimer's Disease Research Center

印第安纳阿尔茨海默病研究中心

• 批准号: 10264429
• 负责人: ANDREW J SAYKIN
• 金额: $ 309.34万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10264429
• 关键词: Address; Aging; Alzheimer' s Disease; Alzheimer' s disease model; Alzheimer' s disease related dementia; Animal Model; Awareness; Biological; Biological Markers; Biological Models; Brain; Caregivers; Clinical; Clinical Trials; Cognition; Collaborations; Communities; Complex; DNA sequencing; Data; Data Science; Data Scientist; Dementia; Development; Diagnosis; Discipline; Disease; Early Diagnosis; Early Intervention; Environment; Environmental Risk Factor; Etiology; Family; Family member; Fostering; Functional disorder; Genetic; Goals; Growth; Healthcare; Heterogeneity; Image; Impaired cognition; Indiana; Individual; Industry; Informatics; Inherited; Interdisciplinary Study; International; Intervention; Leadership; Machine Learning; Maps; Methodology; Methods; Molecular; Molecular Genetics; Nature; Nerve Degeneration; Participant; Pathogenesis; Pathway interactions; Patients; Pharmacology; Phase; Phenotype; Population Heterogeneity; Positioning Attribute; Positron-Emission Tomography; Prevalence; Prevention; Process; Proteomics; Research; Research Infrastructure; Research Personnel; Resource Development; Resources; Risk; Role; Science; Scientific Advances and Accomplishments; Scientist; Staging; Symptoms; Systems Biology; Targeted Research; Therapeutic; Thinking; Time; Training and Education; Translational Research; Translations; Underrepresented Populations; Universities; academic program; advanced analytics; base; biological heterogeneity; brain health; caregiver interventions; clinical phenotype; cognitive testing; cohort; collaborative approach; cost effective; disparity reduction; dosage; early detection biomarkers; effective therapy; imaging biomarker; improved; induced pluripotent stem cell; innovation; lifestyle factors; medical schools; medical specialties; member; metabolomics; method development; mild cognitive impairment; multimodality; multiple omics; neuroimaging; neuropathology; new therapeutic target; non-drug; novel; novel diagnostics; novel strategies; pre-clinical; precision medicine; prevent; programs; racial and ethnic; ranpirnase; recruit; socioeconomic disparity; socioeconomic diversity; stem; success; successful intervention; tau Proteins; therapeutic development; tool development; training opportunity; transcriptome sequencing; translational scientist

Project Summary – IADRC Overall The Indiana Alzheimer’s Disease Research Center (IADRC) was established in 1991 to bring investigators and institutional resources at the Indiana University School of Medicine (IUSM) together to address the fundamental causes and treatment of Alzheimer’s disease (AD) and related dementias (ADRD). Despite many important gains, the need for targeted research is greater than ever, with an estimated 5.8 million people in the U.S. suffering from AD/ADRD. Unfortunately, we do not yet know how to prevent AD or have an approved disease modifying intervention. Both are critical to stem the growth in dementia prevalence. The overarching goal of the IADRC going forward is to support the goal of the NAPA to prevent and effectively treat AD by 2025, through innovative research on etiology, early detection, and therapeutics. Biomarker studies indicate that processes leading to AD begin at least 20 years prior to dementia, suggesting that successful interventions must be implemented early. This presents a potential opportunity for early intervention, but the field is challenged by critical barriers decreasing the prospects of timely success. The IADRC has identified the barriers as: a) The current understanding of etiology and pathophysiology is fragmented and incomplete; b) Sensitive, specific, and cost-effective methods for early detection are not available; c) Therapeutic development is hampered by the heterogeneity and complexity of ADRD; d) Shortage of data and translational scientists; and, e) Inadequate diversity at all levels. The IADRC specific aims entail innovation to overcome these barriers and accelerate research toward prevention and effective treatment: 1) Support, enhance, and expand innovative research on ADRD targeting causes, diagnosis, treatment, and prevention; 2) Provide critical research resources and infrastructure to support existing studies and enable new innovative research, utilizing a well-characterized longitudinal clinical cohort, with prioritization of diverse populations including underrepresented groups (URG) and those in preclinical and early symptomatic phases, including subjective cognitive decline and mild cognitive impairment, which will help to advance the identification of easily accessible biomarkers for early detection; 3) Identify and prioritize novel therapeutic targets from high-throughput approaches with rapid translation to proof- of-concept studies using genetic and other enrichment strategies for better biological targeting and reduction of phenotypic and biological heterogeneity for more efficient and cost-effective clinical trials; 4) Increase the number of investigators with deep expertise in advanced data sciences to bridge cellular/molecular processes of neurodegeneration and clinical phenotypes, as well as clinical and translational researchers who can move therapeutic approaches from model systems to clinical trials; 5) Provide educational and training opportunities related to dementia for a broad array of learners, with special emphasis on increasing participation from URG in ADRD related research and healthcare specialties. The IADRC is well-positioned to help achieve the NIA/NAPA goals through sustained and impactful contributions towards prevention and treatment of AD/ADRD.

项目摘要-IADRC总体 1991年成立了印第安纳州阿尔茨海默氏病研究中心（IADRC） 印第安纳大学医学院（IUSM）的启发资源，以解决基本 尽管许多重要的是，阿尔茨海默氏病（AD）和相关痴呆症（ADRD）的原因和信任 收益，对目标研究的需求比以往任何时候都更大，美国估计有580万人 不幸的是，我们还不知道 修改间隔。 IADRC前进的是支持NAPA的目标，以预防和有效的条约处理AD，到2025年 关于病因，早期检测和治疗学的创新研究。 导致广告至少在痴呆症之前20年开始，建议成功的干预措施必须是 尽早实施。 关键的障碍降低了及时成功的前景。 当前对病因和病理生理学的理解是分散的，b） 没有成本效益的早期检测方法； ADRD的异质性和复杂性； 各种各样的Livingls。 针对预防和有效治疗的研究：1）支持，增强和扩大有关的创新研究 ADRD针对原因，诊断，治疗和预防； 2） 基础架构支持现有研究并启用新的新创新研究，并利用特色良好 纵向临床队列，优先考虑多样的受欢迎的人群，包括代表性不足的群体（URG） 以及那些处于临床前和早期症状阶段的人，即主观认知能力下降和轻度认知 障碍，这将有助于鉴定易于访问的生物标志物的早期发现； 通过快速转化为证明，从高槽方法中识别并确定新的治疗靶标 使用遗传和其他富集策略进行概念研究，以靶向靶向靶向靶向靶向靶向靶向和有一天的研究 表型和生物学异质性更多，以增加更具成本效益的临床试验； 在高级数据科学方面具有深厚专业知识的研究人员的脑子/分子processessssssssssssesses 神经变性和临床表型，以及可以移动的宗派研究人员 从模型系统到临床试验的治疗方法； 5） 与痴呆症有关的各种学习者有关，特别强调了URG的参与 ADRD相关的研究和医疗保健专业。 通过对预防和治疗AD/ADRD的持续和影响力贡献的目标。